CUSABIO) SARS-CoV-2 Spike RBD Nanobody from CUSABIO! Validated in ELISA, GICA, Neutralising
작성자
abbabio
작성일자
2020-07-02
조회수
345
If you are unable to see the message below, click here to view
The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly develop therapeutics and prophylactics against SARS-CoV-2. Accumulating evidences have showed that single-domain antibodies (also known as Nanobodies, Nbs) may serve as useful therapeutics during coronavirus outbreaks. More information about Nbs, please view the article entitled "Nanobody, what a Powerful Novel Antibody!".
Recently, CUSABIO have developed SARS-CoV-2 Spike RBD Nanobody. This antibody has been validated in ELISA, GICA, Neutralising. It can react with samples infected with human coronavirus SARS-CoV-2. This recombinant nanobody is small and stable, which allows for its reaching to hidden epitopes such as crevices of target proteins.
The Binding Activity of SARS-CoV-2 Spike RBD Nanobody with SARS-CoV-2-S1-RBD by functional ELISA. Immobilized SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) at 2 μg/ml can bind SARS-CoV-2 Spike RBD Nanobody, the EC50 is 0.8674 ng/ml.
GICA
In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good.
Activity Assay
Binding signal of SARS-CoV-2 Spike RBD Nanobody and SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) was inhibited by ACE2 protein-HRP conjugated inhibitor (CSB-MP866317HU) with the IC50 is 1.296 nM.
Neutralizing Assay
Binding signal of SARS-CoV-2 Spike RBD Nanobody and SARS-CoV-2-S1-RBD (CSB-YP3324GMY1) was inhibited by ACE2 protein-HRP conjugated inhibitor (CSB-MP866317HU) with the IC50 is 0.1074 μg/ml.
